Arsenic trioxide to prevent relapse after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding arsenic trioxide (a drug) to the standard transplant process can lower the risk of leukemia coming back. It is for people with AML or MDS who have a certain genetic change (TP53 mutation) and are about to have their first stem cell transplant from a matched donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with a specific change in a gene called TP53.
- You are planning to have your very first stem cell transplant using cells from a donor.
- You have a donor match that is 8 out of 8 HLA markers (tissue type).
- Your overall health is good (Karnofsky score of 70% or higher).
- Your heart, lungs, kidney, and liver function meet certain minimum levels (tests will be checked).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral medications, including arsenic trioxide, venetoclax, and a chemotherapy agent (azacitidine or decitabine), for people with certain blood cancers (AML, MDS, or CMML) that have a TP53 gene mutation. The goal is to see if this pill-based treatment can help control the cancer.
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.